Choroidal neovascularization, an uncommon occurrence in children, may complicate up to 20% of cases of closed-globe blunt trauma with Bruch's membrane rupture. Visual outcome in untreated eyes is usually poor, and there is no consensus on the management of this complication. Treatment options include observation, surgical removal of the membrane, photocoagulation, or photodynamic therapy. Antivascular endothelial growth factor therapy has recently been proposed in sporadic adult cases. We report a case of post-traumatic choroidal neovascularization in a boy that has was successfully treated with intravitreal bevacizumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaapos.2011.02.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Secretogranin III: a promising therapeutic target for intraocular neovascular lesions.
Int Ophthalmol
January 2025
Department of Ophthalmology, The Second Hospital of Jilin University, #218 Ziqiang Street, Changchun, 130041, Jilin, China.
Purpose: The purpose of this study is to investigate the role of Secretogranin III (Scg3) in the pathogenesis of intraocular neovascular diseases and assess its potential as a therapeutic target for novel treatment strategies.
Methods: A literature review was conducted to examine the expression of Scg3 in intraocular neovascular diseases. We reviewed studies on the interaction of Scg3 with its homologous receptors and its effect on endothelial cell proliferation, migration, and vascular permeability-key processes involved in angiogenesis and neovascularization.
Neurodegeneration and choroidal vascular features on OCT in the progression to advanced age-related macular degeneration.
Int J Ophthalmol
January 2025
H&TRC-Health & Technology Research Center, ESTeSL Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon 1990-096, Portugal.
Aim: To quantify and compare longitudinal thickness changes of the ganglion cell complex (GCC) and the choroid in patients with different patterns of age-related macular degeneration (AMD) progression.
Methods: Retrospective cohort analysis of anonymized data from participants aged 50y or more and diagnosed with early/intermediate AMD in at least one eye (with no evidence of advanced AMD). A total of 64 participants were included from the Instituto de Retina de Lisboa (IRL) study (IPL/2022/MetAllAMD_ESTeSL) and divided into 4 groups according to the Rotterdam classification for AMD.
Selective Gamma-Secretase Inhibition by CHF5074 Attenuates Inflammation and Neovascularization in a Murine Model of Choroidal Neovascularization.
Curr Eye Res
January 2025
Ophthalmology Department, Peking University People's Hospital, Beijing, China.
Purpose: Chronic inflammation plays an important role in the pathogenesis of choroidal neovascularization (CNV). This study aimed to investigate the effect of the CHF5074, a γ-secretase inhibitor, on angiogenesis in a laser-induced CNV model and elucidate its possible molecular mechanism.
Methods: Male C57/BL6J mice aged between 6 to 8 weeks were employed to set up a laser-induced model of CNV.
One-Year Outcomes in Subjects Developing Macular Neovascularization While Undergoing Avacincaptad Pegol Therapy for Geographic Atrophy.
Clin Ophthalmol
January 2025
Department of Ophthalmology, New Vision Eye Center, Vero Beach, FL, USA.
Purpose: To assess the 12-month outcomes in subjects developing macular neovascularization (MNV) during intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Methods: This research was conducted as a case-controlled, retrospective study of AMD subjects undergoing IVA treatment for GA from two private practice institutions. Subjects were divided into 1) a Study Group of patients who developed MNV and then underwent anti-vascular endothelial growth factor (VEGF) therapy during the study period, and 2) a Control Group of patients who were complication-free during the study period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!